Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

The changing face of gastric cancer: epidemiologic trends and advances in novel therapies

Cancer Gene Therapy volume 28, pages 390–399 (2021)Cite this article

Subjects

Abstract

Gastric cancer is an aggressive solid-tumor malignancy with poor prognosis. The epidemiologic face of gastric cancer is changing and further insight into its heterogenous immunohistopathologic nature is needed to develop personalized therapies for specific patient populations. In this review, we highlight changes in gastric cancer epidemiology with a special emphasis on racial and ethnic variations and discuss the implications of current clinical and preclinical treatment advances.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    Article  PubMed  Google Scholar 

  2. Correa P. Gastric cancer: two epidemics? Dig Dis Sci. 2011;56:1585–6.

    Article  PubMed  Google Scholar 

  3. Wang SC, Yeu Y, Hammer STG, Xiao S, Zhu M, Hong C, et al. Hispanic/Latino patients with gastric adenocarcinoma have distinct molecular profiles including a high rate of germline CDH1 variants. Cancer Res. 2020;80:2114–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. North American Association of Central Cancer Registries. NAACCR Fast Stats: an interactive tool for quick access to key NAACCR cancer statistics. 2019. https://faststats.naaccr.org/selections.php?#Output.

  5. Surveillance E, End Results Program. Cancer Stat Facts: Stomach Cancer. 2019. https://seer.cancer.gov/statfacts/html/stomach.html.

  6. Lui FH, Tuan B, Swenson SL, Wong RJ. Ethnic disparities in gastric cancer incidence and survival in the USA: an updated analysis of 1992-2009 SEER data. Dig Dis Sci. 2014;59:3027–34.

    Article  PubMed  Google Scholar 

  7. Merchant SJ, Kim J, Choi AH, Sun V, Chao J, Nelson R. A rising trend in the incidence of advanced gastric cancer in young Hispanic men. Gastric Cancer. 2017;20:226–34.

    Article  CAS  PubMed  Google Scholar 

  8. Al-Refaie WB, Hu CY, Pisters PW, Chang GJ. Gastric adenocarcinoma in young patients: a population-based appraisal. Ann Surg Oncol. 2011;18:2800–7.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Chang ET, Gomez SL, Fish K, Schupp CW, Parsonnet J, DeRouen MC, et al. Gastric cancer incidence among Hispanics in California: patterns by time, nativity, and neighborhood characteristics. Cancer Epidemiol Biomark Prev. 2012;21:709–19.

    Article  Google Scholar 

  10. Rona KA, Schwameis K, Zehetner J, Samakar K, Green K, Samaan J, et al. Gastric cancer in the young: An advanced disease with poor prognostic features. J Surg Oncol. 2017;115:371–5.

    Article  PubMed  Google Scholar 

  11. Calderillo-Ruiz G, Takahashi A, Herrera M, Padilla A, Trejo E, Ramos-Ramirez M, et al. P-145Gastric cancer in young Latin women: bad prognostic factors and outcomes. Ann Oncol. 2019;30:mdz.155.144.

  12. Lopez-Basave HN, Morales-Vasquez F, Ruiz-Molina JM, Namendys-Silva SA, Vela-Sarmiento I, Ruan JM, et al. Gastric cancer in young people under 30 years of age: worse prognosis, or delay in diagnosis? Cancer Manag Res. 2013;5:31–6.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Bustos-Carpinteyro AR, Oliveira C, Sousa A, Oliveira P, Pinheiro H, Carvalho J, et al. CDH1 somatic alterations in Mexican patients with diffuse and mixed sporadic gastric cancer. BMC Cancer. 2019;19:69.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Grad YH, Lipsitch M, Aiello AE. Secular trends in Helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race/ethnic disparities. Am J Epidemiol. 2012;175:54–9.

    Article  PubMed  Google Scholar 

  15. Ma J, Shen H, Kapesa L, Zeng S. Lauren classification and individualized chemotherapy in gastric cancer. Oncol Lett. 2016;11:2959–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202–9.

  17. Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449–56.

    Article  CAS  PubMed  Google Scholar 

  18. Theuer CP, Kurosaki T, Ziogas A, Butler J, Anton-Culver H. Asian patients with gastric carcinoma in the United States exhibit unique clinical features and superior overall and cancer specific survival rates. Cancer. 2000;89:1883–92.

    Article  CAS  PubMed  Google Scholar 

  19. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57.

    Article  PubMed  Google Scholar 

  20. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21.

    Article  CAS  PubMed  Google Scholar 

  21. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

    Article  CAS  PubMed  Google Scholar 

  22. Lordick F, Janjigian YY. Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol. 2016;13:348–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19:1372–84.

    Article  CAS  PubMed  Google Scholar 

  24. Yang L, Lin PC. Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression. Semin Cancer Biol. 2017;47:185–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, et al. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017;8:761–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Llorca-Cardeñosa MJ, Fleitas T, Ibarrola-Villava M, Peña-Chilet M, Mongort C, Martinez-Ciarpaglini C, et al. Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment. Oncotarget. 2016;7:63424–36.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo C, et al. Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci. 2008;99:121–8.

    CAS  PubMed  Google Scholar 

  28. Chung HW, Lim JB. Role of the tumor microenvironment in the pathogenesis of gastric carcinoma. World J Gastroenterol. 2014;20:1667–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Murata-Kamiya N, Kurashima Y, Teishikata Y, Yamahashi Y, Saito Y, Higashi H, et al. Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene. 2007;26:4617–26.

    Article  CAS  PubMed  Google Scholar 

  30. Liu N, Zhou N, Chai N, Liu X, Jiang H, Wu Q, et al. Helicobacter pylori promotes angiogenesis depending on Wnt/beta-catenin-mediated vascular endothelial growth factor via the cyclooxygenase-2 pathway in gastric cancer. BMC Cancer. 2016;16:321.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Yu H, Zeng J, Liang X, Wang W, Zhou Y, Sun Y, et al. Helicobacter pylori promotes epithelial-mesenchymal transition in gastric cancer by downregulating programmed cell death protein 4 (PDCD4). PLoS ONE. 2014;9:e105306.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Sawayama H, Ishimoto T, Baba H. Microenvironment in the pathogenesis of gastric cancer metastasis. J Cancer Metas Treat. 2018;4.

  33. Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N. Engl J Med. 2018;378:1085–95.

    Article  CAS  PubMed  Google Scholar 

  34. Wang Z, Si X, Xu A, Meng X, Gao S, Qi Y, et al. Activation of STAT3 in human gastric cancer cells via interleukin (IL)-6-type cytokine signaling correlates with clinical implications. PLoS ONE. 2013;8:e75788.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Wu X, Tao P, Zhou Q, Li J, Yu Z, Wang X, et al. IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway. Oncotarget. 2017;8:20741–50.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Kim DY, Cha ST, Ahn DH, Kang HY, Kwon CI, Ko KH, et al. STAT3 expression in gastric cancer indicates a poor prognosis. J Gastroenterol Hepatol. 2009;24:646–51.

    Article  CAS  PubMed  Google Scholar 

  37. Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res. 2000;6:519–25.

    CAS  PubMed  Google Scholar 

  38. Guo Q, Li Q, Wang J, Liu M, Wang Y, Chen Z, et al. A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: a preliminary, three-center, clinical trial study. Medicine (Baltimore). 2019;98:e16234.

    Article  CAS  Google Scholar 

  39. Kemi N, Eskuri M, Herva A, Leppänen J, Huhta H, Helminen O, et al. Tumour-stroma ratio and prognosis in gastric adenocarcinoma. Br J Cancer. 2018;119:435–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17:332.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Kaye SB, Fehrenbacher L, Holloway R, Amit A, Karlan B, Slomovitz B, et al. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin Cancer Res. 2012;18:6509–18.

    Article  CAS  PubMed  Google Scholar 

  42. Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res. 2013;19:258–67.

    Article  CAS  PubMed  Google Scholar 

  43. Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, et al. Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a Hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J Clin Oncol. 2015;33:4284–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Cohen DJ, Christos PJ, Kindler HL, Catenacci DVT, Bekaii-Saab TB, Tahiri S, et al. Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study. J Clin Oncol. 2013;31:4011.

    Article  Google Scholar 

  45. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Shan YQ, Ying RC, Zhou CH, Zhu AK, Ye J, Zhu W, et al. MMP-9 is increased in the pathogenesis of gastric cancer by the mediation of HER2. Cancer Gene Ther. 2015;22:101–7.

    Article  PubMed  CAS  Google Scholar 

  47. Murray GI, Duncan ME, Arbuckle E, Melvin WT, Fothergill JE. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut. 1998;43:791–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Xu J, E C, Yao Y, Ren S, Wang G, Jin H. Matrix metalloproteinase expression and molecular interaction network analysis in gastric cancer. Oncol Lett. 2016;12:2403–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Chen J, Chen LJ, Zhou HC, Yang RB, Lu Y, Xia YL, et al. Prognostic value of matrix metalloproteinase-9 in gastric cancer: a meta-analysis. Hepatogastroenterology. 2014;61:518–24.

    PubMed  Google Scholar 

  50. Shah MA, Ruiz EPY, Bodoky G, Starodub A, Cunningham D, Yip D, et al. A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1). J Clin Oncol. 2019;37:4–4.

    Article  Google Scholar 

  51. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer. 2002;86:1864–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Macedo F, Ladeira K, Longatto-Filho A, Martins SF. Gastric cancer and angiogenesis: is VEGF a useful biomarker to assess progression and remission? J Gastric Cancer. 2017;17:1–10.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Bai ZG, Zhang ZT. A systematic review and meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer. Onco Targets Ther. 2018;11:7077–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29:3968–76.

    Article  CAS  PubMed  Google Scholar 

  55. Kang Y, Kang W, Di Bartolomeo M, Chau I, Yoon H, Cascinu S, et al. LBA43 Randomized phase III ANGEL study of rivoceranib (apatinib)+ best supportive care (BSC) vs placebo+ BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens. Ann Oncol. 2019;30:mdz394.

    Google Scholar 

  56. Zheng X, Song X, Shao Y, Xu B, Chen L, Zhou Q, et al. Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a meta-analysis. Oncotarget. 2017;8:57386–98.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Perrone G, Ruffini PA, Catalano V, Spino C, Santini D, Muretto P, et al. Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer. 2008;44:1875–82.

    Article  CAS  PubMed  Google Scholar 

  58. Kulangara K, Guerrero L, Posch A, Boyer S, Hanks DA, Carnahan J, et al. Investigation of PD-L1 expression and response to pembrolizumab (pembro) in gastric cancer (GC) and cervical cancer (CC) using combined positive score (CPS) and tumor proportion score (TPS). J Clin Oncol. 2018;36:4065–4065.

    Article  Google Scholar 

  59. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4:e180013.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Kulangara K, Zhang N, Corigliano E, Guerrero L, Waldroup S, Jaiswal D, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143:330–7.

    Article  CAS  PubMed  Google Scholar 

  61. Tabernero J, Cutsem EV, Bang Y-J, Fuchs CS, Wyrwicz L, Lee KW, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the phase III KEYNOTE-062 study. J Clin Oncol. 2019;37:LBA4007–LBA4007.

    Article  Google Scholar 

  62. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71.

    Article  CAS  PubMed  Google Scholar 

  63. Iizasa H, Nanbo A, Nishikawa J, Jinushi M, Yoshiyama H. Epstein-Barr Virus (EBV)-associated gastric carcinoma. Viruses. 2012;4:3420–39.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24:1449–58.

    Article  CAS  PubMed  Google Scholar 

  65. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61:673–84.

    Article  CAS  PubMed  Google Scholar 

  66. Murase H, Inokuchi M, Takagi Y, Kato K, Kojima K, Sugihara K. Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer. Mol Clin Oncol. 2014;2:509–17.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Bahleda R, Italiano A, Hierro C, Mita A, Cervantes A, Chan N, et al. Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. Clin Cancer Res. 2019;25:4888–97.

    Article  CAS  PubMed  Google Scholar 

  68. Paik PK, Shen R, Berger MF, Ferry D, Soria JC, Mathewson A, et al. A phase Ib open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers. Clin Cancer Res. 2017;23:5366–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N. Engl J Med. 2019;381:338–48.

    Article  CAS  PubMed  Google Scholar 

  70. Van Cutsem E, Bang YJ, Mansoor W, Petty RD, Chao Y, Cunningham D, et al. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann Oncol. 2017;28:1316–24.

    Article  PubMed  Google Scholar 

  71. Tejani MA, Cheung E, Eisenberg PD, Scott AJ, Tesfaye AA, Dreiling L, et al. Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC). J Clin Oncol. 2019;37:91–91.

    Article  Google Scholar 

  72. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol. 2019;10:2040620719841581.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Shibaguchi H, Luo N, Shirasu N, Kuroki M, Kuroki M. Enhancement of antitumor activity by using a fully human gene encoding a single-chain fragmented antibody specific for carcinoembryonic antigen. Onco Targets Ther. 2017;10:3979–90.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Han Y, Liu C, Li G, Li J, Lv X, Shi H, et al. Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models. Am J Cancer Res. 2018;8:106–19.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Kim M, Pyo S, Kang CH, Lee CO, Lee HK, Choi SU, et al. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. PLoS ONE. 2018;13:e0198347.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Jiang H, Shi Z, Wang P, Wang C, Yang L, Du G, et al. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J Natl Cancer Inst. 2019;111:409–18.

    Article  PubMed  CAS  Google Scholar 

  78. Dottermusch M, Kruger S, Behrens HM, Halske C, Rocken C. Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study. Virchows Arch. 2019;475:563–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Zhan X, Wang B, Li Z, Li J, Wang H, Chen L, et al. Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma. J Clin Oncol. 2019;37:2509.

    Article  Google Scholar 

  80. Al-Batran S-E, Schuler MH, Zvirbule Z, Manikhas G, Lordick F, Rusyn A, et al. FAST: an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol. 2016;34:LBA4001–LBA4001.

    Article  Google Scholar 

  81. Hu J-K, Hospital WC intraperitoneal infusion of EpCAM CAR-T cell in advanced gastric cancer with peritoneal metastasis (WCH-GC-CART). 2018. https://ClinicalTrials.gov/show/NCT03563326.

  82. Ajani JA, Hecht JR, Ho L, Baker J, Oortgiesen M, Eduljee A, et al. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer. 2006;106:1908–16.

    Article  CAS  PubMed  Google Scholar 

  83. Masuzawa T, Fujiwara Y, Okada K, Nakamura A, Takiguchi S, Nakajima K, et al. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 2012;41:1297–304.

    Article  CAS  PubMed  Google Scholar 

  84. Sundar R, Rha SY, Yamaue H, Katsuda M, Kono K, Kim HS, et al. A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. BMC Cancer. 2018;18:332.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  85. Sutter AP, Fechner H. Gene therapy for gastric cancer: is it promising? World J Gastroenterol. 2006;12:380–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Chen JP, Lin C, Xu CP, Zhang XY, Fu M, Deng YP, et al. Molecular therapy with recombinant antisense c-myc adenovirus for human gastric carcinoma cells in vitro and in vivo. J Gastroenterol Hepatol. 2001;16:22–8.

    Article  PubMed  Google Scholar 

  87. Sako A, Kitayama J, Koyama H, Ueno H, Uchida H, Hamada H, et al. Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer. Cancer Res. 2004;64:3624–8.

    Article  CAS  PubMed  Google Scholar 

  88. Ohashi M, Kanai F, Ueno H, Tanaka T, Tateishi K, Kawakami T, et al. Adenovirus mediated p53 tumour suppressor gene therapy for human gastric cancer cells in vitro and in vivo. Gut. 1999;44:366–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Wold WS, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 2013;13:421–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Shimada H, Matsubara H, Shiratori T, Shimizu T, Miyazaki S, Okazumi S, et al. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci. 2006;97:554–61.

    Article  CAS  PubMed  Google Scholar 

  91. Miyake T, Kumasawa K, Sato N, Takiuchi T, Nakamura H, Kimura T. Soluble VEGF receptor 1 (sFLT1) induces non-apoptotic death in ovarian and colorectal cancer cells. Sci Rep. 2016;6:24853.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Zarogoulidis P, Darwiche K, Sakkas A, Yarmus L, Huang H, Li Q et al. Suicide gene therapy for cancer—-current strategies. J Genet Syndr Gene Ther. 2013;4.

  93. Lu M, Freytag SO, Stricker H, Kim JH, Barton K, Movsas B. Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP Trial). Contemp Clin Trials. 2011;32:453–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Cattaneo M, Orlandi R, Ronchini C, Granelli P, Malferrari G, Menard S, et al. The expression of SEL1L and TAN-1 in normal and neoplastic cells. Int J Biol Markers. 2000;15:26–32.

    Article  CAS  PubMed  Google Scholar 

  95. Aberle S, Schug N, Mathlouthi R, Seitz G, Kupper JH, Schroder K, et al. Promoter selection for the cytosine deaminase suicide gene constructs in gastric cancer. Eur J Gastroenterol Hepatol. 2004;16:63–7.

    Article  CAS  PubMed  Google Scholar 

  96. Isomoto H, Ohtsuru A, Braiden V, Iwamatsu M, Miki F, Kawashita Y, et al. Heat-directed suicide gene therapy mediated by heat shock protein promoter for gastric cancer. Oncol Rep. 2006;15:629–35.

    CAS  PubMed  Google Scholar 

  97. Manzanedo I, Pereira F, Rihuete Caro C, Perez-Viejo E, Serrano A, Gutierrez Calvo A, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Ann Surg Oncol. 2019;26:2615–21.

    Article  PubMed  Google Scholar 

  98. Bonnot PE, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a Propensity Score Analysis. J Clin Oncol. 2019;37:2028–40.

    Article  CAS  PubMed  Google Scholar 

  99. Fu DG. Epigenetic alterations in gastric cancer (Review). Mol Med Rep. 2015;12:3223–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Zazula M, Ferreira AM, Czopek JP, Kolodziejczyk P, Sinczak-Kuta A, Klimkowska A, et al. CDH1 gene promoter hypermethylation in gastric cancer: relationship to Goseki grading, microsatellite instability status, and EBV invasion. Diagn Mol Pathol. 2006;15:24–9.

    Article  CAS  PubMed  Google Scholar 

  101. Chen YT, Zhu F, Lin WR, Ying RB, Yang YP, Zeng LH. The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A. Cancer Chemother Pharm. 2016;77:757–65.

    Article  CAS  Google Scholar 

  102. Tan W, Zhou W, Yu HG, Luo HS, Shen L. The DNA methyltransferase inhibitor zebularine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo. Biochem Biophys Res Commun. 2013;430:250–5.

    Article  CAS  PubMed  Google Scholar 

  103. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2’-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000;60:6039–44.

    CAS  PubMed  Google Scholar 

  104. Scott LJ. Azacitidine: a review in myelodysplastic syndromes and acute myeloid leukaemia. Drugs. 2016;76:889–900.

    Article  CAS  PubMed  Google Scholar 

  105. Schneider BJ, Shah MA, Klute K, Ocean A, Popa E, Altorki N, et al. Phase I study of epigenetic priming with azacitidine prior to standard neoadjuvant chemotherapy for patients with resectable gastric and esophageal adenocarcinoma: evidence of tumor hypomethylation as an indicator of major histopathologic response. Clin Cancer Res. 2017;23:2673–80.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, University of Texas, Southwestern Medical Center, Dallas, TX, USA

    Raghav Chandra, Sam Wang, Herbert Zeh & Matthew Porembka

  2. University of Texas, Southwestern Medical School, Dallas, TX, USA

    Neeraja Balachandar

  3. Division of Thoracic Surgery, Department of Cardiovascular and Thoracic Surgery, University of Texas, Southwestern Medical Center, Dallas, TX, USA

    Scott Reznik

Authors
  1. Raghav Chandra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neeraja Balachandar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sam Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Scott Reznik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Herbert Zeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Matthew Porembka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew Porembka.

Ethics declarations

Conflict of interest

None of the authors have conflicts of interest to disclose. MRP is a Dedman Family Scholar in Clinical Care at UTSW.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chandra, R., Balachandar, N., Wang, S. et al. The changing face of gastric cancer: epidemiologic trends and advances in novel therapies. Cancer Gene Ther 28, 390–399 (2021). https://doi.org/10.1038/s41417-020-00234-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41417-020-00234-z

This article is cited by

Search

Advanced search

Quick links